# A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1812 Treatment on Synaptic Activity in Subjects with Mild to Moderate Alzheimerʼs Disease

> **NIH NIH RF1** · COGNITION THERAPEUTICS, INC. · 2022 · $2,144,409

## Abstract

ABSTRACT. Cognition Therapeutics, Inc. (CogRx) is developing ElaytaTM (CT1812), a disease-modifying drug
for Alzheimer’s disease (AD). CT1812 is the first highly brain penetrant selective sigma-2 receptor antagonist
small molecule. This first-in-class drug candidate selectively displaces amyloid-β oligomers bound to neuronal
receptors at synapses and protects synapses from toxic oligomer effects, clearing them from the brain into the
cerebrospinal fluid (CSF). When administered once daily for 28 days to mild to moderate AD patients, CT1812
significantly reduces concentrations of synaptic degeneration markers in AD patient CSF. Based on our review
of publicly-disclosed clinical trial data, no other therapeutic currently in development selectively targets the
most toxic form of the Aβ protein – oligomers. No other AD drug candidate reduces synaptic damage markers
as much, and as rapidly, as CT1812 in Alzheimer's patients.
Our Aim in the proposed trial is to identify non-invasive measures to quantify the CNS impact of CT1812
demonstrated ability to reduce synaptic damage in AD patients. This pilot trial project proposes to evaluate the
effect of one month of CT1812 treatment on quantitative EEG in a Phase 1b randomized double-blind,
placebo-controlled, crossover clinical trial in AD patients. We hypothesize that the rapid reduction in synaptic
damage CSF biomarkers seen in previous clinical trials will be accompanied by a reduction in global theta
power and provide information on the suitability of this sensitive non-invasive qEEG method of measuring
synaptic function for measuring patient response to drug treatment in future efficacy studies. Completion of this
pilot study in AD patients will inform the design and methods of the subsequent Phase 2a proof of concept
trials with CT1812.

## Key facts

- **NIH application ID:** 10651320
- **Project number:** 3RF1AG058710-01A1S1
- **Recipient organization:** COGNITION THERAPEUTICS, INC.
- **Principal Investigator:** ANTHONY O CAGGIANO
- **Activity code:** RF1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $2,144,409
- **Award type:** 3
- **Project period:** 2019-07-01 → 2023-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10651320

## Citation

> US National Institutes of Health, RePORTER application 10651320, A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1812 Treatment on Synaptic Activity in Subjects with Mild to Moderate Alzheimerʼs Disease (3RF1AG058710-01A1S1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10651320. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*